BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24876663)

  • 1. Assessment of urinary osteopontin in association with podocyte for early predication of nephropathy in diabetic patients.
    Al-Malki AL
    Dis Markers; 2014; 2014():493736. PubMed ID: 24876663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
    Li Z; Xu Y; Liu X; Nie Y; Zhao Z
    Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of urinary podocalyxin in early diagnosis of diabetic nephropathy.
    Kostovska I; Trajkovska KT; Cekovska S; Topuzovska S; Kavrakova JB; Spasovski G; Kostovski O; Labudovic D
    Rom J Intern Med; 2020 Dec; 58(4):233-241. PubMed ID: 32780718
    [No Abstract]   [Full Text] [Related]  

  • 4. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.
    Shoukry A; Bdeer Sel-A; El-Sokkary RH
    Mol Cell Biochem; 2015 Oct; 408(1-2):25-35. PubMed ID: 26104579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy.
    Ye H; Bai X; Gao H; Li L; Wu C; Sun X; Zhang C; Shen Y; Zhang J; Lu Z
    J Diabetes Complications; 2014; 28(1):96-100. PubMed ID: 24075693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.
    Gluhovschi C; Gluhovschi G; Petrica L; Timar R; Velciov S; Ionita I; Kaycsa A; Timar B
    J Diabetes Res; 2016; 2016():4626125. PubMed ID: 27413755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary podocyte-associated mRNA profile in Egyptian patients with diabetic nephropathy.
    Fayed A; Rahman Tohamy IA; Kahla H; Elsayed NM; El Ansary M; Saadi G
    Diabetes Metab Syndr; 2019; 13(5):2849-2854. PubMed ID: 31425946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin.
    Hara M; Yamagata K; Tomino Y; Saito A; Hirayama Y; Ogasawara S; Kurosawa H; Sekine S; Yan K
    Diabetologia; 2012 Nov; 55(11):2913-9. PubMed ID: 22854890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary biomarkers for early diabetic nephropathy: beyond albuminuria.
    Lee SY; Choi ME
    Pediatr Nephrol; 2015 Jul; 30(7):1063-75. PubMed ID: 25060761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes.
    Lioudaki E; Stylianou KG; Petrakis I; Kokologiannakis G; Passam A; Mikhailidis DP; Daphnis EK; Ganotakis ES
    Nephron; 2015; 131(1):34-42. PubMed ID: 26340089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy.
    Fukuda A; Minakawa A; Kikuchi M; Sato Y; Nagatomo M; Nakamura S; Mizoguchi T; Fukunaga N; Shibata H; Naik AS; Wiggins RC; Fujimoto S
    Sci Rep; 2020 Oct; 10(1):18209. PubMed ID: 33097787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary Exosomal mRNA of WT1 as Diagnostic and Prognostic Biomarker for Diabetic Nephropathy.
    Abe H; Sakurai A; Ono H; Hayashi S; Yoshimoto S; Ochi A; Ueda S; Nishimura K; Shibata E; Tamaki M; Kishi F; Kishi S; Murakami T; Nagai K; Doi T
    J Med Invest; 2018; 65(3.4):208-215. PubMed ID: 30282862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of two novel renal tubular proteins in type 2 diabetic patients with nephropathy.
    Abdel Ghafar MT; Shalaby KH; Okda HI; Abo El Gheit RE; Soliman NA; Keshk WA
    J Investig Med; 2020 Mar; 68(3):748-755. PubMed ID: 31722957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy.
    Zheng M; Lv LL; Ni J; Ni HF; Li Q; Ma KL; Liu BC
    PLoS One; 2011; 6(5):e20431. PubMed ID: 21655212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of podocytes in patients with diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Ebihara I; Koide H
    Nephrol Dial Transplant; 2000 Sep; 15(9):1379-83. PubMed ID: 10978394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus.
    Vijay S; Hamide A; Senthilkumar GP; Mehalingam V
    Diabetes Metab Syndr; 2018 Sep; 12(5):649-652. PubMed ID: 29673928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
    Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
    Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes.
    Shoji M; Kobayashi K; Takemoto M; Sato Y; Yokote K
    Biomarkers; 2016; 21(2):164-7. PubMed ID: 26635084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy.
    Kimura M; Toyoda M; Saito N; Kaneyama N; Miyatake H; Tanaka E; Komaba H; Hara M; Fukagawa M
    J Diabetes Res; 2019; 2019():9475637. PubMed ID: 30911554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
    Ma RX; Zhao N; Zhang W
    Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):469-73. PubMed ID: 24059992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.